Rapid and potent C5 inhibition achieved with complete and sustained blockage of complement by a single dose of CAN106 Data to be presented at the 14th International Conference on Complement
CANbridge Pharmaceuticals CAN108 New Drug Application/Orphan Drug Registration (NDA/ORD) for Alagille Syndrome Accepted by the Taiwan Food and Drug Administration - read this article along with other careers information, tips and advice on BioSpace
CANbridge Announces Financial Results and Corporate Updates for the Twelve Months Ended December 31, 2021 - read this article along with other careers information, tips and advice on BioSpace